
0:00
10:55
As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast for a conversation on the updated long-term overall survival data from its Phase 1 trial of SYNC-T Therapy SV-102 in patients with metastatic prostate cancer.
Dr Link discusses SYNC-T, their investigational in situ personalised immunotherapy, as well as metastatic castration-resistant (or mCRPC) and metastatic hormone-sensitive (or mHSPC) disease, and the possible outcomes for patients going forward.
Listen to the conversation and keep up on ESMO26 updates here.
Fler avsnitt från "pharmaphorum Podcast"



Missa inte ett avsnitt av “pharmaphorum Podcast” och prenumerera på det i GetPodcast-appen.








